Laminin-211 (LMN-211)

Laminin-211 is a large heterotrimeric extracellular matrix glycoprotein composed of the alpha-2, beta-1, and gamma-1 chains, primarily localized in the basement membranes of skeletal muscle and peripheral nerves [UniProt P24043]. It functions as a critical structural bridge between the extracellular matrix and the muscle cell cytoskeleton by interacting with alpha-dystroglycan and integrin alpha-7-beta-1 [PubMed: 29103389]. This interaction is essential for maintaining sarcolemmal integrity during muscle contraction and for promoting Schwann cell myelination [PubMed: 30111504]. Mutations in the LAMA2 gene lead to a deficiency of Laminin-211, resulting in Congenital Muscular Dystrophy Type 1A (MDC1A), a severe disorder characterized by progressive muscle weakness and white matter abnormalities [NIH: GARD]. Therapeutic approaches under investigation include protein replacement with recombinant Laminin-211, gene therapies using linker proteins like mini-agrin, and small molecules such as Omigapil that target downstream apoptotic pathways [PubMed: 32653528]. These interventions aim to restore the mechanical stability of muscle fibers and prevent the progressive degeneration associated with the loss of matrix-cell signaling.

Other names

Laminin-2MerosinLAMA2-LAMB1-LAMC1 heterotrimerLAMA2-containing laminin

Restoration of the structural linkage between the extracellular matrix and the muscle cell cytoskeleton to prevent sarcolemmal rupture and apoptosis.